Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: Results of a randomized clinical trial

Current Medical Research and Opinion

Volumn 22, Issue 4, 2006, Pages 751-759

  Umpierrez, Guillermo ^a   Issa, Maher ^b   Vlajnic, Aleksandra ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI   (France)

Author keywords

A1C; Fasting plasma glucose; Hypoglycemia; Oral combination therapy; Sulfonylurea; Thiazolidinedione; Type 2 diabetes

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLIMEPIRIDE; GLUCOSE; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 33646234461     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X104786     Document Type: Article

References (45)

1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49) [UK Prospective Diabetes Study (UKPDS) Group]. J Am Med Assoc 1999;281:2005-12
2. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303
3. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. J Am Med Assoc 2002;287:360-72
4. Erle G, Lovise S, Stocchiero C, et al. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients. Acta Diabetol 1999;36:61-5
5. Wyne KL, Drexler AJ, Miller JL, Bell DS, Braunstein S, Nuckolls JG. Constructing an algorithm for managing type 2 diabetes. Focus on role of the thiazolidinediones. Postgrad Med 2003;[Spec No:63-72, review]
6. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99-110
7. Cusi K, Defronzo R. Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89-131
8. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Phys 2001;63:1747-56
9. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001;7:417-50
10. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabetic Med 2000;17:40-7
11. Fonseca V, Rosenstock J, Pattwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000;283:1695-702
12. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study: the Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409
13. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care 1998;21:2050-5
14. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus: the Multicenter Metformin Study Group. New Engl J Med 1995;333:541-9
15. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65
16. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38:636-41
17. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002;25:1607-11
18. Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients [Glimepiride Study Group]. Diabetes Care 1996;19:1194-9
19. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 1996;39:1617-24
20. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001;17:467-73
21. Riddle MC, McDaniel P, Bugos C. First-dose C-peptide response and risk of hypoglycemia are lower with glimepiride than glyburide. Diabetes Care 2001;50:A129
22. Kabadi UM, Kabadi MU. Improvement in lipids with glimepiride in type 2 diabetes mellitus. Diabetes Res 2001;35:155-62
23. Bugos C, Austin M, Viereck C, Atherton T. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res Clin Pract 1999;50:S47
24. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study [The Pioglitazone 001 Study Group]. Diabetes Care 2000;23:1605-11
25. Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems. Health Utilities Index. Pharmacoeconomics 1995;7:490-502
26. Medical Economics. Red book 2003 drug topics: the pharmacist's trusted companion for more than a century (red book drug topics). Toronto (ON): Thomson Healthcare; 2003
27. American Medical Association. Medicare Resource Based Relative Value Scale (RBRVS): the physicians guide 2003. Chicago (IL); 2003
28. Anon. DRG expert, 2003: a comprehensive reference to the DRG classification system, 19th ed. Ingenix; 2002
29. Boccuzzi SJ, Wogen J, Fox J, Sung JC, Shah AB, Kim J. Utilization of oral hypoglycemic agents in a drug-insured US population. Diabetes Care 2001;24:1411-5
30. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study [The Pioglitazone 027 Study Group]. Clin Ther 2000:22:1395-409
31. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabetic Med 2001;18:828-34
32. Rendell MS, Glazer NB, Ye Z. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with type 2 diabetes: influence of prior antidiabetic drug regimen. J Diabetes Complications 2003;17:211-7
33. Kahn SE. Clinical review 135. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-58
34. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58
35. Yki-Jarvinen H. Thiazolidinediones. New Engl J Med. 2004;351:1106-18
36. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: beyond glucose-level lowering. J Cardiovasc Risk 1999;6:337-46
37. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001;56:265-94
38. Riddle MC, Rosenstock JR. Oral monotherapy and combination therapy. In: Cefalu W, Gerich JE, LeRoith D, editors. The CADRE handbook of diabetes management. New York: Medical Information Press; 2004. p. 127-44
39. Mudaliar S, Henry R. Combination therapy for type 2 diabetes. Endocrine Practice 1999;5:208-19
40. Avandamet [package insert]. Physicians' desk reference. Montvale (NJ): Thomson PDR; 2005. p. 1433-8
41. Avandia [package insert]. Physicians' desk reference. Montvale (NJ): Thomson PDR; 2005.p. 1438-43
42. Actos [package insert]. Physicians' desk reference. Montvale (NJ): Thomson PDR; 2005. p. 3181-5
43. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1988;47:507-14
44. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-53
45. Zhang BB, Moller DE. New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 2000;4:461-7